Sees FY24 U.S Humira sales $7.4B, down $400M from prior view. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks ...

Humira is starting to feel the effects of lower-cost biosimilar competition in some markets however, with sales falling for the first time in the second quarter of this year. The FDA approval for ...

The company expects Humira's annual sales to stabilize between $4 billion and $5 billion post-exclusivity loss, a substantial decline from its peak. This erosion puts pressure on AbbVie to rapidly ...

This could lead to a more rapid decline in Humira sales than currently projected, potentially impacting AbbVie's ability to offset losses with growth from other products in its portfolio.